Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in *mdx* mice

Russell G. Rogers, …, Michael I. Lewis, Eduardo Marbán

*JCI Insight.* 2019;4(11):e130202. [https://doi.org/10.1172/jci.insight.130202](https://doi.org/10.1172/jci.insight.130202).

**Corrigendum**

Original citation: *JCI Insight.* 2019;4(7):e125754. [https://doi.org/10.1172/jci.insight.125754](https://doi.org/10.1172/jci.insight.125754)
Citation for this corrigendum: *JCI Insight.* 2019;4(11):e130202.
[https://doi.org/10.1172/jci.insight.130202](https://doi.org/10.1172/jci.insight.130202)
Eduardo Marbán’s conflict-of-interest statement was not included in the manuscript. The authors apologize for the oversight. The correct statement is below. EM declares ownership of Capricor Therapeutics stock (self and spouse) and salary to his spouse from Capricor Therapeutics. He is also the inventor on one awarded (US 9,828,603) and two relevant pending (US 15/516,658 and PCT/US2018/028148) patent applications assigned to Cedars-Sinai Medical Center. The authors regret the error.

Find the latest version:

[http://jci.me/130202/pdf](http://jci.me/130202/pdf)
Corrigendum

Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice

Russell G. Rogers, Mario Fournier, Lizbeth Sanchez, Ahmed G. Ibrahim, Mark A. Aminzadeh, Michael I. Lewis, and Eduardo Marbán


Citation for this corrigendum: JCI Insight. 2019;4(11):e130202. https://doi.org/10.1172/jci.insight.130202.

Eduardo Marbán's conflict-of-interest statement was not included in the manuscript. The authors apologize for the oversight. The correct statement is below.

EM declares ownership of Capricor Therapeutics stock (self and spouse) and salary to his spouse from Capricor Therapeutics. He is also the inventor on one awarded (US 9,828,603) and two relevant pending (US 15/516,658 and PCT/US2018/028148) patent applications assigned to Cedars-Sinai Medical Center.

The authors regret the error.